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Abstract
NK cells are innate lymphoid cells, which play a key role in the immune response
to cancer and pathogens and participate in the shaping of adaptive immunity. NK
cells engage in a complex bidirectional interaction with myelomonocytic cells. In
particular, macrophages, dendritic cells and neutrophils promote differentiation
and effector function of NK cells and, on the other hand, myelomonocytic cells
express triggers of checkpoint blockade (eg PD‐L1) and other immunosuppressive
molecules, which negatively regulate NK cell function. In addition, NK cells
express high levels of IL‐1R8, which acts as a checkpoint for IL‐18 driven differ-
entiation and activation of NK cells. Evidence suggests that targeting the myeloid
cell‐NK cell crosstalk unleashes effective anti‐tumour and anti‐viral resistance.
1 | INTRODUCTION
Natural killer cells (NK) are innate lymphoid cells that play
a key role in the immune responses against cancer and
pathogens.1,2 NK cell activation depends on a delicate bal-
ance between activating and inhibitory signals and the inte-
gration of these pathways may prevent NK self‐reactivity
and governs NK cell activation in the presence of cells in
“distress”.3,4 NK cells, once activated, can be actively cyto-
toxic through the release of perforin and granzymes and
can secrete cytokines, such as IFNγ, thus participating in
the shaping of the adaptive immune responses.4-8 NK cell
effector functions also include antibody‐dependent cell
cytotoxicity (ADCC): NK cells recognize antibody‐coated
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target cells through the FcγRIIIA (CD16), which is coupled
to CD3ζ and FcRγ transducing chains bearing the ITAM
(immunoreceptor tyrosine‐based activation motif)
domains.3,9 NK cells recognize damaged, stressed, infected
or tumour cells, which upregulate or express de novo
ligands interacting with activating NK cell receptors.
Stress‐induced ligands on host cells, such as human ULBP
and MIC or mouse RAE1, H60 and MULT1 molecules can
interact with the activating receptor NKG2D on NK cells.10
Other ligands of activating receptors are viral encoded non-
self ligands, which include cytomegalovirus‐encoded m157,
directly recognized by Ly49H in the mouse, and TLR
ligands, even though the direct role of TLRs in NK cells
remains an unsettled issue.11-15 The natural cytotoxicity
receptors (NCR), such as NKp46/NCR1, NKp44/NCR2
and NKp30/NCR3, which are linked to ITAM‐bearing
CD3ζ, FcRγ or DAP12, are other potent activating recep-
tors, playing a major role in tumour/leukaemia cell lysis.
NKp46 was reported to interact with influenza‐ and parain-
fluenza‐derived hemagglutinins.16 NCR also interact with
soluble ligands with either agonist or antagonist activity.
For example, PDGF‐DD and Nidogen‐1 bind to NKp44
inducing NK cell activation and inhibition, respec-
tively.17,18 Finally, a role for other activating receptors such
as DNAM‐1 belonging to the nectin family and 2B4
belonging to the SLAM family have been also described.4
NK cell inhibitory receptors prevent auto‐reactivity
while allowing recognition and killing of stressed target
cells. NK cells express several MHC class I‐specific inhibi-
tory receptors that include the lectin‐like Ly49 dimers in
the mouse, the killer cell immunoglobulin‐like receptors
(KIRs) in humans and the CD94‐NKG2A heterodimers in
both species, all sharing the intra‐cytoplasmic inhibitory
ITIMs (immunoreceptor tyrosine‐based inhibition motifs)
domains.19-21 Other NK cell inhibitory receptors act in a
MHC class I independent manner.21-23 NK cells can sense
the lack of MHC class I occurring in virally infected or
tumour cells and this process is called the “missing self”
recognition.24,25 Thus, healthy cells that express MHC class
I molecules and low levels of stress‐induced molecules are
protected from NK cell killing, whereas cells “in distress”
that upregulate stress‐induced ligands and downregulate
MHC class I molecules are recognized and killed.23,26,27
The acquisition of NK cell tolerance to self depends on the
expression of MHC class I specific‐inhibitory receptors and
on the “education” or “licensing” system. NK cell educa-
tion occurs during NK cell development and leads to the
prevention of auto‐reactivity, ensuring the generation of
self‐tolerant killer cells.28-30 As NK cell receptors do not
undergo somatic recombination, their potential for auto‐
reactivity is due to the fact that the expression pattern of
MHC class I receptors is largely random and is controlled
by the education process. Some NK cells lack inhibitory
receptors that recognize MHC class I, and/or express acti-
vating receptors that recognize self ligands, including MHC
molecules.20 During the education process, NK cells that
lack self MHC‐specific inhibitory receptors become
hyporesponsive. For instance, in mice or humans that lack
MHC class I molecules, NK cells fail to kill MHC class‐I
deficient autologous cells and display reduced responses to
other stimulations.31-33 NK cells that express receptors
specific for MHC are properly functional, as they are
responsive to activating signals, but still tolerant to self
cells, because of the interaction between inhibitory recep-
tors and their MHC ligands.34,35 The intensity and quality
of NK cell response reflect the number of self‐MHC inhibi-
tory receptors as well as of activating receptors expressed
by NK cells and their ligands on target cells.
Finally, the functional activation of NK cells is modu-
lated through the crosstalk with other leucocytes. Thanks to
the broad repertoire of pattern recognition molecules,
phagocytes have the potential to recognize a variety of
microbial moieties of bacterial, fungal, viral and parasite
origin, as well as damage‐associated molecular patterns.
They can sense infections and tissue damage, thus activat-
ing innate immune responses and orienting adaptive
immune responses. Innate immune activation leads to
release of cytokines and other soluble mediators, and to
induction of cell‐to‐cell contacts among leucocytes and
other cell types, such as endothelial cells. NK cell
responses are affected by the cytokine microenvironment
and the interaction with other immune cells, such as den-
dritic cells (DCs), macrophages, neutrophils and T cells.
IL‐12, IL‐18, IL‐15 and type I IFN are strong activators of
NK cell effector functions and IL‐2 favours NK cell prolif-
eration and activation (Figure 1). CD4+ T cell‐produced
IL‐2 in lymph nodes, and DC and macrophage‐derived IL‐
18 and IL‐15 activate NK cells, whereas T regulatory cell‐
derived TGFβ negatively regulates NK cell functions. It
has been appreciated that, despite their original definition
as natural killers, NK cells do require “priming” to gain a
full activation state. IL‐15 and IL‐18 are well‐described
mediators of NK cell priming in both steady state and
inflammatory conditions.36-44
NK cell maturation drives the acquisition of several
chemotactic receptors and adhesion molecules, allowing
NK cells to migrate from the bone marrow through the
blood to spleen, liver, lung, lymph nodes, omentum and
uterus during gestation.45,46 Tissue‐specific NK cells are
functionally diverse and this is dependent on intrinsic fac-
tors, related to the distinct NK cell subsets found in differ-
ent organs and extrinsic factors, in particular, mediators
derived by other resident cells and leucocytes. This, in turn,
influences NK cell interaction with other cell types.46
Here, we will focus on the interplay between phago-
cytes and NK cells, and on the impact of this crosstalk on
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NK cell and phagocyte responses in both physiological and
pathological conditions.
2 | THE INTERACTION BETWEEN
NK CELLS AND MACROPHAGES
Macrophages are able to prime NK cells through soluble
factors and cell‐to‐cell contact and, in turn, NK cells can
produce several inflammatory mediators, thus shaping the
tissue microenvironment and influencing macrophage func-
tional skewing 47 (Figure 1). In response to in vitro stimu-
lation with cytokines and bacterial products, macrophages
undergo M1 (classical) or M2 (alternative) activation,
which represent the two extremes of a continuous spectrum
of functional activation. Functional skewing of mononu-
clear phagocytes occurs in vivo either under physiological
conditions, such as ontogenesis and pregnancy or in patho-
logical processes, such as allergic and chronic inflamma-
tion, tissue repair, infection and cancer. Mirroring the Th1/
Th2 paradigm, classical activation, generating M1 macro-
phages occurs in the presence of Toll‐like receptor (TLR)
ligands and Th1 cytokines, such as IFNγ, one of effector
molecules released by NK cells. On the contrary, alterna-
tive M2 activation is dependent on Th2 cytokines, such as
IL‐4 and IL‐13. Although phagocytosis is a key mechanism
shared by both classically and alternatively activated
macrophages, functional activation of macrophages leads to
cytotoxicity and killing of the pathogen in M1 macro-
phages, whereas it favours M2‐like macrophage‐dependent
tissue repair, healing, regeneration and angiogenesis.48-50
Macrophages and NK cells can interact in a contact‐de-
pendent manner through the generation of a sort of immune
synapse. Indeed, clustering of receptors and adhesion mole-
cules, such as ICAM‐1 and LFA‐1, expressed respectively
by human macrophages and NK cells, as well as accumula-
tion of F‐actin, was observed at the site of contact in
in vitro co‐culture.51 Regarding soluble mediators, through
in vitro studies with mouse cells, in the early 1990s, it was
demonstrated that macrophage‐produced TNFα and IL‐12
induced the secretion of IFNγ by NK cells,52 whereas
macrophage TGFβ production inhibited lung NK cell acti-
vation.53 Then, IL‐12, IL‐18, IL‐15 and IL‐23 emerged as
the key cytokines responsible for NK cell activation and
their prominent role was originally demonstrated using
macrophages infected in vitro with different pathogens.44,47
Indeed, several studies showed that macrophages stimulated
with TLR agonists,54-56 infected with parasites (Plasmod-
ium falciparum and Leishmania),57,58 viruses (influenza A
virus, Sendai virus, human cytomegalovirus)59 or bacteria
(Salmonella, Mycobacterium tuberculosis, Enterococcus
faecalis, Staphylococcus aureus, Lactobacillus, Streptococ-
cus pneumoniae and Bacillus anthracis)60-65 induced NK
cell activation, leading to CD69 expression, IFNγ produc-
tion and degranulation. The interaction between NK cell
2B4 and macrophage CD48 was reported to be critical for
the induction of NK cell proliferation and IFNγ production,
but not of NK cell cytotoxicity.66 Moreover, it was
observed that upon priming with IL‐2 and IL‐15 produced
by accessory cells, IL‐12 and IL‐18, both secreted by
Salmonella‐infected macrophages, induced a full NK cell
activation in vitro.60 Interestingly, they observed that
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FIGURE 1 NK cell activation
mediated by dendritic cells, neutrophils and
macrophages. Both soluble factors and cell‐
to‐cell contact are involved in the induction
or boosting of NK cell effector functions.
DCs, neutrophils and macrophages produce
IL‐12, IL‐18, IFNβ, TNFα and IL‐15 which
induce NK cell activation. IFNβ is
responsible for the production of IL‐15,
which can occur not only in DCs but also
in NK cells themselves
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IL‐12Rβ2 co‐localized with actin at the immune synapse,
suggesting the importance of cell‐to‐cell contact, as reported
for IL‐15 in DCs and IL‐18 in DCs and macrophages 38-
40,67 (see below). Another group showed that macrophages
infected with Salmonella produced high levels of IL‐23, IL‐
18 and IL‐1β and these cytokines stimulated NK cells to
produce IFNγ and GM‐CSF. IFNγ and GM‐CSF, in turn,
could stimulate the production of IL‐23 and IL‐12p70 by
monocytes and macrophages, confirming the importance of
the NK cell‐macrophage interplay during Salmonella infec-
tion.68 Lopez‐Botet et al59 analysed the effect of functional
polarization of macrophages in the activation of NK cells,
in response to cytomegalovirus infection. NK cells were
highly cytotoxic against both proinflammatory (M1‐like)
and antiinflammatory (M2‐like) infected macrophages, gen-
erated in the presence of GM‐CSF and M‐CSF, respec-
tively. In contrast, IFNγ production was only induced by
M1 infected macrophages. Cytotoxicity was triggered by
NKp46, DNAM‐1 and 2B4 activation, whereas IFNγ pro-
duction was partially dependent on IL‐12 produced by
macrophages.59 Finally, NK cells were demonstrated to be
activated by LPS‐tolerant macrophages. Indeed, NK cells
co‐cultured with LPS‐stimulated macrophages expressed
high levels of NKG2D, which, in turn, promoted the recog-
nition and the lysis of overactivated macrophages through
various NKG2D ligands, such as UL16‐binding proteins
(ULBP1, ULBP2 and ULBP3) and MHC class I‐related
chain A (MICA).51 NK cells have been shown to have cyto-
toxic activity against allogeneic and autologous human
microglial cells. This cytotoxicity was mediated by perforin
and dependent on NKG2D and NKp46 engagement and
counterbalanced by MHC class I binding inhibitory NK cell
receptors. In contrast with macrophages that are resistant to
autologous NK cell cytotoxicity unless they are activated by
TLR ligands,51 microglial activation by LPS was associated
with upregulation of MHC class I molecules and resistance
to NK cell‐mediated killing.69
Mattiola et al41 dissected the crosstalk between human
NK cells and autologous in vitro ‐derived macrophages,
unveiling a complex network of interactions. It was shown
that resting NK cells were primed to produce IFNγ and
expressed higher levels of CD107a and CD69 upon co‐cul-
ture with classically activated M1 macrophages or treatment
with M1‐conditioned media.41 IL‐1β and IFNβ production
by M1 macrophages was responsible for the induction of
NKp44 and NKG2D in NK cells and interestingly, IFNβ
induced IL‐15 cis‐presentation in NK cells, consequently
enhancing IFNγ production. The triggering of NK cell acti-
vating receptors NKp30, NKG2D and 2B4 by M1 macro-
phages was also involved in cell‐to‐cell contact‐dependent
NK cell activation. Finally, it was observed that M1‐primed
NK cells could, in turn, promote type 1 macrophage skew-
ing, even reverting alternative M2 polarization.41
Bellora et al38,56 showed that in vitro resting M0 and
alternatively activated M2 macrophages reprogrammed
towards a classical M1 phenotype through LPS treatment
were able to induce NK cell activation, in terms of cytotox-
icity, IFNγ production, CD69 expression, IL‐2 responsive-
ness and migration through acquisition of CCR7 expression
(Figure 2). IFNγ production was demonstrated to be
induced by DNAM‐1 and 2B4 pathways in a contact‐
dependent manner and, interestingly by IL‐18 expressed as
a membrane‐bound form on macrophages.38,56 In turn, acti-
vated human NK cells were able to kill autologous macro-
phages in vitro through NKp46 and DNAM‐1.38 In
particular, M1 macrophages were more resistant to lysis
compared to M0 and M2 macrophages and this was due to
inhibition of NK cells mediated by higher expression of
HLA class I molecules in M1‐polarizing conditions.56
Macrophage‐NK cell crosstalk is also an important com-
ponent of the immune response against cancer. NK cells
have a key role in the inhibition of tumour progression,
through cytotoxic activity and IFNγ production, whereas
macrophages recruited in tumours can exert both pro‐tu-
moural and anti‐tumoural activity, depending on their
polarization state.49,70 In this regard, Bellora et al71 anal-
ysed the interaction between tumour‐associated macro-
phages (TAMs) from ascites of ovarian cancer patients and
NK cells. Untreated TAMs induced low upregulation of
CD69 and CD25 in NK cells, whereas LPS‐treated TAMs
regained the capacity to fully activate NK cells, in terms of
CD69, CCR7, CD25 expression and IFNγ production.
Indeed, LPS‐treated TAMs activated NK cell‐dependent
lysis of a NK cell‐resistant ovarian cancer cell line
(OVCAR‐3), possibly through IL‐12/IL‐18‐induced IFNγ
production.71
These studies underline that in type 1‐oriented immune
responses, NK cells amplify both innate and adaptive
responses, as a result of their interaction with classically
activated M1‐polarized macrophages.
3 | SUPPRESSION OF NK CELL
FUNCTION BY MACROPHAGES
It has long been known that myelomonocytic cells can
suppress NK cell activity either as a result of tissue driven
differentiation, as shown originally for lung alveolar
macrophages,72 or of skewed activation.73 In particular,
TAMs are endowed with an armamentarium of immuno-
suppressive molecules, including triggers of checkpoint
blockade.49 Pesce74 identified a subset of NK cells
expressing PD‐1, which triggers functional inhibition.
Recent evidence indicated that in Hodgkin's lymphoma
macrophage‐expressed PD‐L1 is a major driver of NK cell
suppression.73 Macrophage‐mediated suppression of NK
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cells can also be mediated by other complementary path-
ways such as TGFβ and prostaglandins (Figure 3).
Recently, a single‐cell analysis of early lung adenocarci-
noma lesions revealed a poor infiltration of NK cells in
tumour lesions compared to normal lung and a nonfunc-
tional state of the infiltrating NK cells, in terms of IFNγ,
granzyme B and CD57 expression. T cell activation was
compromised and T regulatory cells were enriched. Inter-
estingly, the impaired NK and T cell anti‐tumour immunity
was associated with a suppressive phenotype of myeloid
cells, indicated by the enrichment of PPARγhigh macro-
phages and depletion of CD16+ monocytes and CD141+
dendritic cells.75
Although most of these data have been generated
in vitro, macrophage functional polarization states does
occur in vivo,50,75 suggesting the importance of myeloid
cell plasticity and dynamic changes in physiological and
pathological conditions, in particular in cancer, and affect-
ing other cell types such as NK cells.
4 | THE INTERACTION OF NK
CELLS AND DENDRITIC CELLS
NK cells were originally defined as spontaneous cytotoxic
innate lymphocytes, able to quickly kill target cells, with-
out the need of any prior sensitization, differently from T
cells, whose killing mechanism is antigen specific and
MHC‐restricted. In spite of this, the concept of NK cell
priming has emerged and the interplay between NK cells
and DCs was identified as a crucial mechanism involved in
NK cell priming.1,76-78
In particular, it was shown that functional interactions
between DCs and NK cells occur. DCs are required for
Ly49H+ NK cell accumulation in mouse cytomegalovirus
infection and for proper NK cell response in Herpes sim-
plex virus‐1 infection.79-82
It was reported by the Diefenbach's group that DCs were
required for NK cell response to pathogens in vivo and NK
cell priming occurred upon IL‐15 trans‐presentation by
DCs.67 DCs constitutively expressed the IL‐15/IL‐15Rα
complex, which was required for NK cell homeostasis and
could be induced by type I IFNs in inflammatory conditions,
favouring NK cell priming. Interestingly, it was then
observed that IFNβ‐induced IL‐15/IL‐15Rα expression
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FIGURE 2 IL‐18 as a central player in
NK cell activation. IL‐18 is a crucial
proinflammatory cytokine promoting NK
cell activation. M0 and M2 macrophages
express a membrane‐bound form of IL‐18
(mIL‐18), which is released upon treatment
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FIGURE 3 Suppression of NK cell function by macrophages.
Among inhibitory pathways in NK cells, those regulated by
macrophages have been emphasized: NK cell suppression mediated
by TAM‐derived PGE2, TGFβ and the engagement of PD‐1 by
macrophage‐expressed PD‐L1. MΦ, macrophage; TAM, tumour‐
associated macrophage
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occurred not only in DCs, but also in NK cells themselves,
allowing IL‐15 cis‐presentation and NK cell activation39
(Figure 1). Remarkably, NK cell activation was impaired
when both trans‐ and cis‐presented IL‐15 was lacking,
whereas NK cell survival and homeostasis relied on a NK
cell extrinsic, IL‐15‐dependent mechanism.39,83,84 LPS‐ or
E. coli‐triggered DCs produced IL‐2, IL‐18 and IFNβ that
were crucial not only to prime but indeed to induce a full
activation state of NK cells, which were unable to directly
sense LPS. Close contacts between DCs and NK cell in the
lymph nodes were essential for the localized delivery of DC‐
derived IL‐18 to NK cells40 (see below). DC‐derived IL‐2,
IL‐18 and IFNβ were also fundamental to elicit NK cell cyto-
toxic responses, both in vivo in bacterial and viral infections
and in vitro.39,85,86
In certain inflammatory or infectious conditions, NK
cells can be involved in the regulation of the adaptive
response, through the killing of immature DCs, which
would lead to an improper T cell activation. Immature DCs
express lower levels of MHC‐I molecules compared to
mature DCs, being therefore more susceptible to NK cell‐
mediated recognition. Defective interactions between NK
cells and DCs, and impaired NK cell‐mediated lysis of
autologous immature DCs have been observed in HIV‐1‐
infected viremic patients.87 The defective lysis was due to
reduced expression of NKp30 and TNF‐related apoptosis‐
inducing ligand (TRAIL) in NK cells, particularly in a
CD56-CD16+ subset.88 Moreover, mature DCs from vire-
mic patients had reduced capacity to secrete IL‐10 and IL‐
12 and to prime NK cell proliferation and activation.88
5 | NK CELLS AND NEUTROPHILS
The interplay between neutrophils and NK cells has
recently emerged as a crucial mechanism regulating innate
and adaptive responses (Figure 1). In different contexts,
neutrophils were reported to be able to both activate and
suppress NK cells.89 Several groups demonstrated that neu-
trophil‐derived ROS and arginase I could compromise the
effector functions of NK cells, in particular of the CD56low
NK cell subset.90-95 In contrast, lactoferrin, elastase and
other neutrophil granule‐contained proteins were able to
induce NK cell activation and cytotoxicity.96,97
in vivo models of bacterial infections revealed that neu-
trophil production of proinflammatory cytokines, such as IL‐
12, IL‐15 and possibly IL‐18, is crucial to polarize the
immune response and favours NK cell‐mediated IFNγ pro-
duction.98,99 In agreement, in vitro experiments showed that
human TLR‐stimulated neutrophils were involved in NK cell
activation in an inflammasome‐dependent manner.99 In turn,
neutrophil‐stimulated NK cells were able to activate DCs,
which then promoted T cell IFNγ production and
proliferation, unveiling a complex interplay between innate
and adaptive immune cells.99 Moreover, it was recently
observed that neutrophils are part of a network of interac-
tions with 6‐sulfo LacNAc+ dendritic cells (slanDCs) and
NK cells, in which neutrophils induced IL‐12 production by
slanDCs via CD18/ICAM‐1, which in turn promoted NK cell
activation.100 The authors also showed direct NK cell‐neutro-
phil interaction, which occurred through ICAM‐3 and CD18,
respectively, and led to IFNγ production by NK cells.100 In
line with this, in mice lacking neutrophils and in patients
with autoimmune or severe congenital neutropenia NK cells
displayed an immature and hyporesponsive phenotype.101
In a murine model of osteoarthritis, an early accumulation
of NK cells and neutrophils was observed in the synovium
and was associated with a worse disease progression. In this
context, neutrophils expressing CXCL10 were responsible
for CXCR3‐mediated NK cell activation and recruitment in
the inflamed joint.102
On the other hand, in vitro experiments revealed that
human stimulated NK cells were able to prolong neutrophil
survival inhibiting apoptosis, favour neutrophil activation, in
terms of ROS production and phagocytic activity, and medi-
ate the upregulation of activation markers.103,104 NK cell‐
produced IFNγ, GM‐CSF and TNFα were responsible for
the enhanced neutrophil survival and activation, as shown by
increased expression of activation markers (CD11b, CD69
and CD64 upregulation, and CD62L shedding).103,104 In
agreement, NK cells were shown to produce neutrophil
chemo‐attractants, such as CXCL8, CCL3, CCL4 and
CCL5.105,106 In contrast with these studies, it was reported
that NK cells induced neutrophil apoptosis through NKp46
and Fas pathway.107 Whether human NK cells have the abil-
ity to regulate neutrophils in pathologies characterized by a
relevant infiltration of both cell types remains to be eluci-
dated. NK cell‐mediated regulation of neutrophil function in
the mouse has been mostly characterized in NK cell‐depleted
mice. However, controversial results have been reported,
possibly because of the use of different models of disease
and NK cell depletion, and because of the contribution of
other cell types, as carefully reviewed by Cassatella.89 In the
context of cancer, it was recently reported in a sarcoma trans-
plantable model that NK cells regulated neutrophil functions
via IFNγ. Upon NK cell depletion, neutrophils produced
increased levels of VEGF‐A, therefore promoting angiogene-
sis and tumour progression.108
6 | Il‐18 AS A CENTRAL PLAYER IN
NK CELL‐PHAGOCYTE CROSSTALK
IL‐18 was first described as “interferon γ (IFNγ)‐inducing
factor.” IL‐18 is a member of the IL‐1 family, produced as
an immature form and requiring caspase‐1‐mediated
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cleavage to gain bioactivity.109 IL‐18 is a key cytokine
implicated in innate and adaptive type 1 responses and
plays a crucial role in the interplay between macrophages/
DCs and NK cells.109
In this regard, in vitro M‐CSF‐derived resting M0 and
alternatively activated M2 macrophages express a mem-
brane‐bound form of IL‐18, which can be released as a sol-
uble form (sIL‐18) upon stimulation with LPS. The release
of sIL‐18 was shown to be dependent on a protease‐
mediated shedding of the membrane‐bound protein.38
Macrophage‐derived IL‐18 promoted NK cell activation
and CCR7 expression and therefore migration towards
lymph nodes (Figure 2). Interestingly, endotoxin tolerant
macrophages, which are generated with chronic exposure
to TLR ligands, lacked the expression of mIL‐18 and did
not release relevant amounts of sIL‐18, being therefore
unable to activate NK cells.38
Recently, it was elegantly shown in a tumour model
that lymph node‐resident NK cells are activated by DCs
within the lymph node, upon LPS exposure.40 DC‐acti-
vated NK cells are the ones that preferentially egress the
lymph node, then reach the tumour site and exert anti‐
tumour effector functions. Interestingly, two‐photon micro-
scopy analysis revealed that prolonged interactions
occurred between NK cells and DCs in the peripheral T
cell area of the lymph node, in response to LPS treatment.
IL‐18 was previously shown to be produced by activated
DCs and be secreted at the immune synapse generated
between DCs and NK cells. The authors demonstrated that
LPS‐activated DCs, in turn, activate NK cells through IL‐
18, which requires cell‐to‐cell proximity and the formation
of a proper and stable interaction to exert its function 40
(Figure 2).
In line with this findings, we reported that NK cells
deficient of IL‐1R8, a negative regulator of the IL‐1 recep-
tor and TLR family members,110 display enhanced matura-
tion and effector functions, in terms of IFNγ production
and cytotoxicity in tumour and viral infection models.111
The increased NK cell differentiation and activation
observed in the absence of IL‐1R8 was dependent on the
IL‐18 pathway, both in basal levels and in tumour models.
Co‐culture experiments of NK cells and CpG‐ or LPS‐
primed bone marrow‐derived DCs revealed that NK cell
activation was mainly dependent on IL‐18 in both IL‐1R8‐
competent and deficient conditions (Figure 2). Moreover,
IL‐1R8‐deficient NK cell phenotype after co‐culture was
abolished upon IL‐18 neutralization. Importantly, IL‐1R8‐
deficient NK cells were protective in a model of sarcoma‐
derived lung metastases and colorectal cancer‐derived liver
metastases and the phenotype was abolished upon neutral-
ization or genetic deletion of IL‐18.111 Moreover, IL‐1R8‐
deficiency unleashed NK cell‐mediated resistance against
MCMV.111
Collectively, these evidences highlight the crucial con-
tribution of IL‐18 in the regulation of NK cell activation in
the interplay with macrophages and DCs.
7 | CONCLUSIONS
NK cells are innate lymphoid cells with cytotoxic potential
against cancer or virally infected cells. Engagement of vari-
ous activating and inhibitory receptors on the NK cell with
ligands present on the target cell surface, initiates balanced
signalling pathways leading to NK cell function or toler-
ance. In addition, NK cells engage bidirectional interactions
with other leucocytes, including macrophages, DCs and
neutrophils, which affect both cell types. Macrophage‐NK
cell crosstalk is an important component of the immune
response against microbes and cancer. In particular, in type
1‐oriented immune responses, NK cells amplify both innate
and adaptive responses, as a result of their interaction with
M1‐polarized macrophages. Furthermore, the interaction
with DCs and trans‐presented cytokines represents a crucial
mechanism leading to NK cell priming and full activation.
Similarly, the interaction between NK cells and neutrophils
through soluble mediators and adhesion molecules, influ-
ences NK cell maturation and responsiveness, as well as
neutrophil survival. In addition to IL‐12 and IL‐15, IL‐18
is emerging as a key myeloid cell‐derived factor involved
in the activation of NK cells. IL‐18 activity is tightly regu-
lated by IL‐1R8, a negative regulator of the IL‐1 receptor
family, acting as a novel checkpoint of the anti‐viral and
anti‐tumour functions of NK cells, both against primary
liver tumours and metastasis.
Given the diversity and complexity of myeloid cell
functional polarization, NK‐myeloid cell crosstalk can
result in diverse functional outcomes in a site‐ and context‐
specific manner. The development of high‐throughput tech-
nologies allowing a detailed and unbiased characterization
of cell types and functional states and dissecting macro-
phage complexity beyond the M1 and M2 paradigm will
be crucial to deeply understand the yin‐yang of NK and
myeloid cells interactions.
In a translational perspective, these bidirectional interac-
tions with phagocytes, myeloid‐derived factors, and their
regulation must be taken into account to fully exploit the
potential of NK cells to restrain primary cancer and metas-
tasis.
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